FABP4 and atherosclerosis: Studies have reported on various FABP4 inhibitors being synthesised for the treatment of diabetes and atherosclerosis, including derivatives of niacin, quinoxaline, aryl-quinoline, bicyclic pyridine, urea, aromatic compounds, and other heterocyclic compounds (Floresta et al. 2017).